NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb. 21, 2006--Advaxis, Inc. (OTCBB: ADXS) announced that regulators have allowed the company to initiate Phase I/II clinical testing with its lead compound, Listeria-based cancer vaccine, Lovaxin C. Lovaxin C, which specifically targets cervical cancer in women, will be tested for the first time in humans in this study.
